Abstract
DNA vaccines are a next generation branch of vaccines which offer major benefits over their conventional counterparts. However, to be effective in large mammals and humans, an enhancing delivery technology is required. Electroporation is a physical technique which results in improved delivery of large molecules through the cell membrane. In the case of plasmid DNA, electroporation enhances both the uptake and expression of the delivered DNA. The skin is an attractive tissue for DNA vaccination in a clinical setting due to the accessibility of the target, the ease of monitoring, and most importantly the immunocompetent nature of the dermis. Electroporation in the skin has the benefit of being minimally invasive and generally well tolerated. Previous studies have determined that optimized electroporation parameters (such as electrical field intensity, pulse length, pulse width, and plasmid formulation) majorly impact the efficiency of DNA delivery to the skin. We provide an overview of DNA vaccination in skin and muscle. In addition, we detail a protocol for the successful intradermal electroporation of plasmid DNA to guinea pig skin, an excellent dermatological animal model. The work detailed here suggests that the technique is safe and effective and could be highly applicable to a clinical setting.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Widera G, Austin M, Rabussay D et al (2000) Increased DNA vaccine delivery and immunogenicity by electroporation in vivo. J Immunol 164:4635–4640
Prud’homme GJ, Draghia-Akli R, Wang Q (2007) Plasmid-based gene therapy of diabetes mellitus. Gene Ther 14:553–564
Otten G, Schaefer M, Doe B et al (2004) Enhancement of DNA vaccine potency in rhesus macaques by electroporation. Vaccine 22:2489–2493
Mathiesen I (1999) Electropermeabilization of skeletal muscle enhances gene transfer in vivo. Gene Ther 6:508–514
Bagarazzi ML, Yan J, Morrow MP et al (2012) Immunotherapy against HPV16/18 generates potent TH1 and cytotoxic cellular immune responses. Sci Transl Med 4:155ra138
El-Kamary SS, Billington M, Deitz S et al (2012) Safety and tolerability of the Easy Vax clinical epidermal electroporation system in healthy adults. Mol Ther 20:214–220
Andre S, Seed B, Eberle J et al (1998) Increased immune response elicited by DNA vaccination with a synthetic gp120 sequence with optimized codon usage. J Virol 72:1497–1503
Deml L, Bojak A, Steck S et al (2001) Multiple effects of codon usage optimization on expression and immunogenicity of DNA candidate vaccines encoding the human immunodeficiency virus type 1 Gag protein. J Virol 75:10991–11001
Muthumani K, Zhang D, Dayes NS et al (2003) Novel engineered HIV-1 East African Clade-A gp160 plasmid construct induces strong humoral and cell-mediated immune responses in vivo. Virology 314:134–146
Schneider R, Campbell M, Nasioulas G et al (1997) Inactivation of the human immunodeficiency virus type 1 inhibitory elements allows Rev-independent expression of Gag and Gag/protease and particle formation. J Virol 71:4892–4903
Yang JS, Kim JJ, Hwang D et al (2001) Induction of potent Th1-type immune responses from a novel DNA vaccine for West Nile virus New York isolate (WNV-NY1999). J Infect Dis 184:809–816
Miyazaki S, Miyazaki J (2008) In vivo DNA electrotransfer into muscle. Dev Growth Differ 50:479–483
Draghia-Akli R, Khan AS, Cummings KK et al (2002) Electrical enhancement of formulated plasmid delivery in animals. Technol Cancer Res Treat 1:365–372
Gothelf A, Gehl J (2010) Gene electrotransfer to skin; review of existing literature and clinical perspectives. Curr Gene Ther 10:287–299
Charoo NA, Rahman Z, Repka MA et al (2010) Electroporation: an avenue for transdermal drug delivery. Curr Drug Deliv 7:125–136
Lin F, Shen X, Kichaev G et al (2012) Optimization of electroporation-enhanced intradermal delivery of DNA vaccine using a minimally invasive surface device. Hum Gene Ther Methods 23:157–168
Broderick KE, Shen X, Soderholm J et al (2011) Prototype development and preclinical immunogenicity analysis of a novel minimally invasive electroporation device. Gene Ther 18:258–265
Andersen P, Doherty TM (2005) The success and failure of BCG — implications for a novel tuberculosis vaccine. Nat Rev Microbiol 3:656–662
Flynn PM, Shenep JL, Mao L et al (1994) Influence of needle gauge in Mantoux skin testing. Chest 106:1463–1465
Acknowledgments
The authors would like to thank Janess Mendoza for help with the animal procedures. This work was supported by Inovio Pharmaceuticals (Blue Bell, PA).
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer Science+Business Media New York
About this protocol
Cite this protocol
Broderick, K.E., Khan, A.S., Sardesai, N.Y. (2014). DNA Vaccination in Skin Enhanced by Electroporation. In: Rinaldi, M., Fioretti, D., Iurescia, S. (eds) DNA Vaccines. Methods in Molecular Biology, vol 1143. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-0410-5_8
Download citation
DOI: https://doi.org/10.1007/978-1-4939-0410-5_8
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-0409-9
Online ISBN: 978-1-4939-0410-5
eBook Packages: Springer Protocols